BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 17483368)

  • 1. The hinge region regulates DNA binding, nuclear translocation, and transactivation of the androgen receptor.
    Haelens A; Tanner T; Denayer S; Callewaert L; Claessens F
    Cancer Res; 2007 May; 67(9):4514-23. PubMed ID: 17483368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collocation of androgen receptor gene mutations in prostate cancer.
    Buchanan G; Greenberg NM; Scher HI; Harris JM; Marshall VR; Tilley WD
    Clin Cancer Res; 2001 May; 7(5):1273-81. PubMed ID: 11350894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and mechanistic characterization of a novel selective nuclear androgen receptor exporter for the treatment of prostate cancer.
    Narayanan R; Yepuru M; Szafran AT; Szwarc M; Bohl CE; Young NL; Miller DD; Mancini MA; Dalton JT
    Cancer Res; 2010 Jan; 70(2):842-51. PubMed ID: 20068182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ARA24/Ran enhances the androgen-dependent NH2- and COOH-terminal interaction of the androgen receptor.
    Harada N; Ohmori Y; Yamaji R; Higashimura Y; Okamoto K; Isohashi F; Nakano Y; Inui H
    Biochem Biophys Res Commun; 2008 Aug; 373(3):373-7. PubMed ID: 18565325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A differential ligand-mediated response of green fluorescent protein-tagged androgen receptor in living prostate cancer and non-prostate cancer cell lines.
    Nakauchi H; Matsuda K; Ochiai I; Kawauchi A; Mizutani Y; Miki T; Kawata M
    J Histochem Cytochem; 2007 Jun; 55(6):535-44. PubMed ID: 17312014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor mutants detected in recurrent prostate cancer exhibit diverse functional characteristics.
    Chen G; Wang X; Zhang S; Lu Y; Sun Y; Zhang J; Li Z; Lu J
    Prostate; 2005 Jun; 63(4):395-406. PubMed ID: 15617028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.
    Dehm SM; Regan KM; Schmidt LJ; Tindall DJ
    Cancer Res; 2007 Oct; 67(20):10067-77. PubMed ID: 17942941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial androgen insensitivity with phenotypic variation caused by androgen receptor mutations that disrupt activation function 2 and the NH(2)- and carboxyl-terminal interaction.
    Quigley CA; Tan JA; He B; Zhou ZX; Mebarki F; Morel Y; Forest MG; Chatelain P; Ritzén EM; French FS; Wilson EM
    Mech Ageing Dev; 2004; 125(10-11):683-95. PubMed ID: 15541764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiandrogens prevent stable DNA-binding of the androgen receptor.
    Farla P; Hersmus R; Trapman J; Houtsmuller AB
    J Cell Sci; 2005 Sep; 118(Pt 18):4187-98. PubMed ID: 16141232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The hinge region in androgen receptor control.
    Clinckemalie L; Vanderschueren D; Boonen S; Claessens F
    Mol Cell Endocrinol; 2012 Jul; 358(1):1-8. PubMed ID: 22406839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator.
    Nishimura K; Ting HJ; Harada Y; Tokizane T; Nonomura N; Kang HY; Chang HC; Yeh S; Miyamoto H; Shin M; Aozasa K; Okuyama A; Chang C
    Cancer Res; 2003 Aug; 63(16):4888-94. PubMed ID: 12941811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia increases androgen receptor activity in prostate cancer cells.
    Park SY; Kim YJ; Gao AC; Mohler JL; Onate SA; Hidalgo AA; Ip C; Park EM; Yoon SY; Park YM
    Cancer Res; 2006 May; 66(10):5121-9. PubMed ID: 16707435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unfaithfulness and promiscuity of a mutant androgen receptor in a hormone-refractory prostate cancer.
    Monge A; Jagla M; Lapouge G; Sasorith S; Cruchant M; Wurtz JM; Jacqmin D; Bergerat JP; Céraline J
    Cell Mol Life Sci; 2006 Feb; 63(4):487-97. PubMed ID: 16456618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligospermic infertility associated with an androgen receptor mutation that disrupts interdomain and coactivator (TIF2) interactions.
    Ghadessy FJ; Lim J; Abdullah AA; Panet-Raymond V; Choo CK; Lumbroso R; Tut TG; Gottlieb B; Pinsky L; Trifiro MA; Yong EL
    J Clin Invest; 1999 Jun; 103(11):1517-25. PubMed ID: 10359561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells.
    Heitzer MD; DeFranco DB
    Cancer Res; 2006 Jul; 66(14):7326-33. PubMed ID: 16849583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An S296R mutation in the human androgen receptor causes activation of the receptor by non-androgenic steroids and stronger inhibition by the nuclear receptor corepressor N-coR.
    Li YD; Lu Y; Chen GC; Lu J
    Clin Exp Pharmacol Physiol; 2008 Oct; 35(10):1252-7. PubMed ID: 18637017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GRIP1 mediates the interaction between the amino- and carboxyl-termini of the androgen receptor.
    Shen HC; Buchanan G; Butler LM; Prescott J; Henderson M; Tilley WD; Coetzee GA
    Biol Chem; 2005 Jan; 386(1):69-74. PubMed ID: 15843149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel mutation F826L in the human androgen receptor in partial androgen insensitivity syndrome; increased NH2-/COOH-terminal domain interaction and TIF2 co-activation.
    Wong HY; Hoogerbrugge JW; Pang KL; van Leeuwen M; van Royen ME; Molier M; Berrevoets CA; Dooijes D; Dubbink HJ; van de Wijngaart DJ; Wolffenbuttel KP; Trapman J; Kleijer WJ; Drop SL; Grootegoed JA; Brinkmann AO
    Mol Cell Endocrinol; 2008 Sep; 292(1-2):69-78. PubMed ID: 18656523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
    Buchanan G; Birrell SN; Peters AA; Bianco-Miotto T; Ramsay K; Cops EJ; Yang M; Harris JM; Simila HA; Moore NL; Bentel JM; Ricciardelli C; Horsfall DJ; Butler LM; Tilley WD
    Cancer Res; 2005 Sep; 65(18):8487-96. PubMed ID: 16166329
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.